FDA Files Renewal Applications for VLN® Tobacco Products
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Source: Newsfilter
- Regulatory Progress: The FDA has accepted 22nd Century Group's MRTP renewal applications for VLN®King and VLN®Menthol King, marking a significant advancement in the company's tobacco harm reduction efforts, with expectations for continued market authorization.
- Market Data Support: The renewal submission includes a 2024 study indicating a 40% reduction in daily cigarette consumption over 12 weeks among smokers using VLN® cigarettes, providing strong support for the long-term commercial and regulatory case for the product.
- Unique Product Positioning: VLN® cigarettes contain 95% less nicotine than traditional cigarettes, with the FDA noting that using such products could help reduce nicotine dependence, further solidifying the company's competitive advantage in the tobacco market.
- Public Engagement: The FDA has begun releasing application materials for public access and opened a docket for public comments, allowing stakeholders to participate in the scientific review process, which enhances the rigor of the FDA's regulatory framework and provides transparency and trust for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XXII?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XXII
About XXII
22nd Century Group, Inc. is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes. The Company manufactures and distributes combustible tobacco products containing minimally or non-addictive levels of nicotine. Additionally, the Company provides turnkey contract manufacturing of cigarettes and filtered cigars for other established tobacco brands. The Company's product, VLN cigarette has 95% less nicotine than the traditional cigarette. The Company operates through a single segment named Tobacco. It is engaged in contract manufacturing organization (CMO) customer contracts that consist of obligations to manufacture the customers' branded filtered cigars and cigarettes. It is also engaged in the sale of its proprietary low nicotine content cigarettes, sold under the brand name VLN, or research cigarettes sold under the brand name SPECTRUM.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Files Renewal Applications for VLN® Tobacco Products
- Regulatory Progress: The FDA has accepted 22nd Century Group's MRTP renewal applications for VLN®King and VLN®Menthol King, marking a significant advancement in the company's tobacco harm reduction efforts, with expectations for continued market authorization.
- Market Data Support: The renewal submission includes a 2024 study indicating a 40% reduction in daily cigarette consumption over 12 weeks among smokers using VLN® cigarettes, providing strong support for the long-term commercial and regulatory case for the product.
- Unique Product Positioning: VLN® cigarettes contain 95% less nicotine than traditional cigarettes, with the FDA noting that using such products could help reduce nicotine dependence, further solidifying the company's competitive advantage in the tobacco market.
- Public Engagement: The FDA has begun releasing application materials for public access and opened a docket for public comments, allowing stakeholders to participate in the scientific review process, which enhances the rigor of the FDA's regulatory framework and provides transparency and trust for the company.
See More
22nd Century Group Reports Disappointing Q1 Earnings
- Earnings Miss: 22nd Century Group reported a Q1 GAAP EPS of -$5.07, missing expectations by $3.87, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company generated $4.11 million in revenue for Q1, a 31% year-over-year decrease that fell short of the $4.6 million forecast, reflecting poor market performance and potential liquidity issues ahead.
- Stock Reaction: Following the earnings report, shares of 22nd Century dropped 18% in after-hours trading, signaling heightened investor concerns about the company's growth prospects, which may impact its financing capabilities and competitive position.
- Future Strategy: Despite the disappointing earnings, 22nd Century plans to launch Pinnacle Pure in 2026 and double its store count, demonstrating a long-term strategic intent to expand in the VLN market; however, short-term financial pressures may hinder execution capabilities.
See More
22ND CENTURY GROUP INC Reports Q1 EPS from Continuing Operations at $-5.07
- Financial Performance: Century Group Inc. reported earnings per share (EPS) of $5.07 for the first quarter.
- Market Context: The EPS figure reflects the company's performance amidst current market conditions.
See More
22ND CENTURY GROUP INC Reports Q1 Net Revenues Rise to $4.1 Million from $3.5 Million
- Revenue Growth: Century Group Inc. reported a net revenue increase to $4.1 million, up from $3.5 million.
- Financial Performance: The significant rise in revenue indicates a positive trend in the company's financial performance for the quarter.
See More
22nd Century to Announce Q1 Earnings on May 7
- Earnings Announcement Schedule: 22nd Century is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimate at -$1.20 and revenue expected at $4.61 million, reflecting a 22.7% year-over-year decline, indicating significant profitability challenges ahead.
- Historical Performance Review: Over the past two years, 22nd Century has failed to meet EPS estimates 100% of the time, although it has surpassed revenue expectations 75% of the time, highlighting a relative strength in revenue management but a pressing need for improvement in profitability.
- Market Reaction Analysis: The company's reduced nicotine strategy has not gained investor confidence, leading to poor stock performance, which may impact its future financing capabilities and market expansion plans.
- Future Strategic Planning: 22nd Century aims to double its store count and launch the Pinnacle Pure product by 2026 to drive VLN market expansion; if successful, this strategy could enhance market share and brand influence.
See More
22nd Century Group Outlines 2026 Strategy and Shareholder Value Initiatives
- Market Opportunity: With approximately 28 million smokers in the U.S. and 70% wanting to quit, 22nd Century Group's VLN® cigarettes, containing 95% less nicotine, cater to this demand for healthier options, potentially driving significant sales growth.
- Product Innovation: The VLN® cigarette is the only FDA-authorized low-nicotine combustible cigarette, proven to help smokers reduce nicotine intake after 28 years of research, establishing the company as a leader in tobacco harm reduction.
- Marketing Expansion: In 2026, the company plans to increase its retail footprint and enhance sales density in existing markets, which is expected to significantly boost awareness of VLN® products and help carve out new market niches in the competitive tobacco industry.
- Long-term Value Creation: The company is committed to driving long-term shareholder value through a diversified low-nicotine product portfolio and strong distribution networks, ensuring all stakeholders understand the importance of its technology in transforming smoking and nicotine addiction.
See More
FDA Files Renewal Applications for VLN® Tobacco Products
- Regulatory Progress: The FDA has accepted 22nd Century Group's MRTP renewal applications for VLN®King and VLN®Menthol King, marking a significant advancement in the company's tobacco harm reduction efforts, with expectations for continued market authorization.
- Market Data Support: The renewal submission includes a 2024 study indicating a 40% reduction in daily cigarette consumption over 12 weeks among smokers using VLN® cigarettes, providing strong support for the long-term commercial and regulatory case for the product.
- Unique Product Positioning: VLN® cigarettes contain 95% less nicotine than traditional cigarettes, with the FDA noting that using such products could help reduce nicotine dependence, further solidifying the company's competitive advantage in the tobacco market.
- Public Engagement: The FDA has begun releasing application materials for public access and opened a docket for public comments, allowing stakeholders to participate in the scientific review process, which enhances the rigor of the FDA's regulatory framework and provides transparency and trust for the company.
See More
22nd Century Group Reports Disappointing Q1 Earnings
- Earnings Miss: 22nd Century Group reported a Q1 GAAP EPS of -$5.07, missing expectations by $3.87, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company generated $4.11 million in revenue for Q1, a 31% year-over-year decrease that fell short of the $4.6 million forecast, reflecting poor market performance and potential liquidity issues ahead.
- Stock Reaction: Following the earnings report, shares of 22nd Century dropped 18% in after-hours trading, signaling heightened investor concerns about the company's growth prospects, which may impact its financing capabilities and competitive position.
- Future Strategy: Despite the disappointing earnings, 22nd Century plans to launch Pinnacle Pure in 2026 and double its store count, demonstrating a long-term strategic intent to expand in the VLN market; however, short-term financial pressures may hinder execution capabilities.
See More
22ND CENTURY GROUP INC Reports Q1 EPS from Continuing Operations at $-5.07
- Financial Performance: Century Group Inc. reported earnings per share (EPS) of $5.07 for the first quarter.
- Market Context: The EPS figure reflects the company's performance amidst current market conditions.
See More
22ND CENTURY GROUP INC Reports Q1 Net Revenues Rise to $4.1 Million from $3.5 Million
- Revenue Growth: Century Group Inc. reported a net revenue increase to $4.1 million, up from $3.5 million.
- Financial Performance: The significant rise in revenue indicates a positive trend in the company's financial performance for the quarter.
See More
22nd Century to Announce Q1 Earnings on May 7
- Earnings Announcement Schedule: 22nd Century is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimate at -$1.20 and revenue expected at $4.61 million, reflecting a 22.7% year-over-year decline, indicating significant profitability challenges ahead.
- Historical Performance Review: Over the past two years, 22nd Century has failed to meet EPS estimates 100% of the time, although it has surpassed revenue expectations 75% of the time, highlighting a relative strength in revenue management but a pressing need for improvement in profitability.
- Market Reaction Analysis: The company's reduced nicotine strategy has not gained investor confidence, leading to poor stock performance, which may impact its future financing capabilities and market expansion plans.
- Future Strategic Planning: 22nd Century aims to double its store count and launch the Pinnacle Pure product by 2026 to drive VLN market expansion; if successful, this strategy could enhance market share and brand influence.
See More
22nd Century Group Outlines 2026 Strategy and Shareholder Value Initiatives
- Market Opportunity: With approximately 28 million smokers in the U.S. and 70% wanting to quit, 22nd Century Group's VLN® cigarettes, containing 95% less nicotine, cater to this demand for healthier options, potentially driving significant sales growth.
- Product Innovation: The VLN® cigarette is the only FDA-authorized low-nicotine combustible cigarette, proven to help smokers reduce nicotine intake after 28 years of research, establishing the company as a leader in tobacco harm reduction.
- Marketing Expansion: In 2026, the company plans to increase its retail footprint and enhance sales density in existing markets, which is expected to significantly boost awareness of VLN® products and help carve out new market niches in the competitive tobacco industry.
- Long-term Value Creation: The company is committed to driving long-term shareholder value through a diversified low-nicotine product portfolio and strong distribution networks, ensuring all stakeholders understand the importance of its technology in transforming smoking and nicotine addiction.
See More
